Neurology News

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

Daily treatment with risdiplam over 24 months resulted in improved motor function and achievement of developmental motor milestones in infants with type 1 spinal muscular atrophy, according to a study published in The Lancet Neurology.

Empyrean Neuroscience Inc. has announced its launch as a genetic engineering company dedicated to developing fungi- and plant-based therapeutics for the treatment of neuropsychiatric and neurologic disorders.

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.

Among patients with systemic sclerosis, those on work disability and who experience greater levels of fatigue are more likely to perceive cognitive dysfunction, according to data published in Arthritis Care & Research.

The FDA has granted breakthrough device designation to neurotechnology company Axoft for its brain-machine interface to treat long-term neurological disorders.

LAS VEGAS — Certain red flags can indicate that a patient’s headaches are the migraine type, Merle Diamond, MD, said at PAINWeek 2022.

Theranica Bio-electronics announced positive top-line results from a double-blind, randomized, placebo-controlled, multicenter clinical trial to evaluate efficacy and safety of Nerivio for the treatment of episodic and chronic migraine.

Patients with hypertension who received angiotensin receptor blocking therapy had a significant decrease in incidence of epilepsy, researchers reported in JAMA Neurology.

Patients with stroke due to nontraumatic intracerebral hemorrhage had significantly higher rates of major adverse cardiovascular events, researchers reported in JAMA Network Open.